Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves Β· freshest Wall Street data, updated daily View live feed β†’
Analyst Tracker/Matthew Weston
UBS

Matthew Weston

Wall Street Analyst
β˜…β˜…β˜…β˜…β˜…
#221
on 13Foresight Β· ranked by our own returns
67%
Success Rate
+3.8%
Average Return
41 of 61 calls profitable Β· +2.6% vs benchmark
S&P 500 (SPY)
πŸ“ˆ Across the calls we could measure, roughly 67% of Matthew Weston's ratings turned a profit when each position was held for 1 year β€” averaging +3.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

58 Buy 77 Hold 0 Sell
Matthew's Stock Coverage 16 ratings Β· 2026-11-18
Company Date Position Consensus β“˜ Price Target β“˜ 1-Yr Return vs S&P 500 β“˜
GB:GSK
GlaxoSmithKline
Oct 29, 2026 HOLD Hold
+5.2% avg upside
26 analysts
$1940.00
4.66% Upside
+5.4% Β·
CH:NOVN
Novartis AG
Oct 28, 2026 HOLD Buy
-15.0% avg upside
32 analysts
$130.00
2.87% Downside
+2.6% Β·
DE:SRT3
Sartorius
Oct 23, 2026 BUY Strong Buy
-0.2% avg upside
19 analysts
$300.00
2.84% Upside
+0.4% Β·
CH:ROP
Roche Holding AG
Oct 23, 2026 BUY Buy
-12.1% avg upside
24 analysts
$376.00
6.80% Downside
+3.2% Β·
DE:MRK
Merck KGaA
Oct 15, 2026 HOLD Buy
-7.2% avg upside
34 analysts
$150.00
0.90% Downside
+3.7% Β·
DE:BAYN
Bayer
Oct 15, 2026 BUY Strong Buy
+8.7% avg upside
31 analysts
$62.00
23.47% Upside
+27.1% Β·
GB:0QIU
Novo Nordisk
Oct 15, 2026 HOLD Hold
+52.9% avg upside
29 analysts
$332.00
24.79% Upside
Β· Β·
FR:DIM
Sartorius Stedim Biotech
Oct 15, 2026 BUY Strong Buy
+19.8% avg upside
12 analysts
$260.00
16.37% Upside
+3.8% Β·
FR:SAN
Sanofi
Oct 15, 2026 HOLD Buy
+21.3% avg upside
30 analysts
$78.00
2.12% Downside
+21.8% Β·
CH:GALD
Galderma Group AG
Sep 10, 2026 BUY Strong Buy
-0.1% avg upside
12 analysts
$200.00
3.78% Upside
+23.5% Β·
GB:AZN
AstraZeneca
Aug 04, 2026 BUY Strong Buy
+7.8% avg upside
28 analysts
$17600.00
26.11% Upside
+16.6% Β·
MRK
Merck & Company
Nov 01, 2024 BUY Strong Buy
-3.5% avg upside
44 analysts
$125.00
16.49% Downside
-12.5% Β·
CH:LONN
Lonza Group Ltd
Jan 27, 2022 BUY Strong Buy
+1.1% avg upside
21 analysts
$750.00
16.45% Upside
-15.1% Β·
FR:IPN
Ipsen
Feb 11, 2020 HOLD Hold
-20.5% avg upside
17 analysts
$72.00
54.41% Downside
+7.8% Β·
NVO
Novo Nordisk
Nov 02, 2018 HOLD Buy
+188.3% avg upside
26 analysts
$310.00
674.99% Upside
+32.3% Β·
NVS
Novartis
Jul 05, 2017 SELL Hold
-16.0% avg upside
24 analysts
β€” +4.0% Β·
πŸ”’ 11 more ratings β€” with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Matthew Weston β€” Frequently Asked Questions
How accurate are Matthew Weston's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Matthew's ratings were profitable over a one-year hold, with an average return of +3.8% per rating, or +2.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Matthew ranked on 13Foresight?
Matthew Weston is currently ranked #221 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge β€” so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matthew cover?
Matthew most recently has ratings on GB:GSK, CH:NOVN, DE:SRT3, CH:ROP, DE:MRK, DE:BAYN, GB:0QIU, FR:DIM, FR:SAN, CH:GALD, GB:AZN, MRK and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.